Modality
Nanobody
MOA
SGLT2i
Target
PRMT5
Pathway
Hedgehog
PompeCSU
Development Pipeline
Preclinical
~Mar 2014
→ ~Jun 2015
Phase 1
~Sep 2015
→ ~Dec 2016
Phase 2
Mar 2017
→ Jan 2028
Phase 2Current
NCT08698214
1,104 pts·CSU
2017-03→2028-01·Terminated
1,104 total pts1 indication
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (1)
2028-01-151.8y awayPh2 Data· CSU
Trial Timeline
2017Q2Q3Q42018Q2Q3Q42019Q2Q3Q42020Q2Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2
P2
Termina…
Catalysts
Ph2 Data
2028-01-15 · 1.8y away
CSU
Terminated|StartCompletionToday
Trials (1)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT08698214 | Phase 2 | CSU | Terminated | 1104 | PANSS |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| Nirarelsin | Johnson & Johnson | Phase 2 | PRMT5 | |
| JNJ-8232 | Johnson & Johnson | NDA/BLA | MALT1 | |
| MRK-853 | Merck & Co | Phase 1 | PRMT5 | |
| Bemalucimab | Bristol-Myers Squibb | Phase 1/2 | Aβ | |
| Geliderotide | Sanofi | Phase 1/2 | PRMT5 | |
| Capifutibatinib | Sanofi | Approved | PRMT5 | |
| NVO-9615 | Novo Nordisk | Phase 2/3 | PRMT5 | |
| Suracagene | GSK | Phase 3 | PRMT5 | |
| BAY-3308 | Bayer | Phase 1 | ALK | |
| Elrarapivir | Vertex Pharma | NDA/BLA | PRMT5 |